K Number
K133557
Device Name
JULIET LL LATERAL LUMBAR CAGE
Manufacturer
Date Cleared
2014-02-03

(76 days)

Product Code
Regulation Number
888.3080
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
JULIET®LL Lumbar Interbody Device is indicated for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). This device is to be used with autogenous bone graft. JULIET®LL Lumbar Interbody Device is to be used with supplemental fixation. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage
Device Description
The JULIET®LL Lateral Lumbar cages are rectangle-shaped intervertebral body fusion devices with a central cavity that can be filled with bone graft (autograft) to facilitate fusion. The JULIET®LL intervertebral body fusion spacer comes in various sizes and footprints in order to fulfill surgeons' needs and accommodate different patient anatomies. The JULIET®LL system is made of PEEK Optima conforming to ASTM F2026 with spikes made of Titanium 6Al-4V ELI conforming to ASTM F136 and ISO 5832-3 and Tantalum markers conforming ASTM F560.
More Information

Not Found

No
The summary describes a passive implantable device made of PEEK and titanium, with no mention of software, algorithms, or any features that would suggest the use of AI or ML. The performance studies are mechanical tests, not related to data analysis or image processing.

Yes.
The device is indicated for intervertebral body fusion procedures for degenerative disc disease, which falls under therapeutic intervention.

No.
This device is an intervertebral body fusion device (cage) used for surgical treatment of degenerative disc disease, not for diagnosis. It is intended to facilitate fusion, not to identify or measure health conditions.

No

The device description clearly states it is a physical intervertebral body fusion device made of PEEK, Titanium, and Tantalum, which are hardware components.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use clearly describes a surgical implant for spinal fusion. This is a therapeutic procedure, not a diagnostic test performed on samples from the body.
  • Device Description: The device is a physical implant made of PEEK, Titanium, and Tantalum, designed to be placed between vertebrae. This is consistent with a surgical device, not a diagnostic one.
  • Lack of IVD Characteristics: There is no mention of the device being used to examine specimens (blood, tissue, etc.) or to provide information about a patient's health status through in vitro testing.

IVD devices are used to perform tests on samples taken from the human body to provide information for diagnosis, monitoring, or screening. This device is a surgical implant used to treat a condition.

N/A

Intended Use / Indications for Use

JULIET®LL Lumbar Interbody Device is indicated for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). This device is to be used with autogenous bone graft. JULIET®LL Lumbar Interbody Device is to be used with supplemental fixation. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage

Product codes (comma separated list FDA assigned to the subject device)

MAX

Device Description

The JULIET®LL Lateral Lumbar cages are rectangle-shaped intervertebral body fusion devices with a central cavity that can be filled with bone graft (autograft) to facilitate fusion. The JULIET®LL intervertebral body fusion spacer comes in various sizes and footprints in order to fulfill surgeons' needs and accommodate different patient anatomies. The JULIET®LL system is made of PEEK Optima conforming to ASTM F2026 with spikes made of Titanium 6Al-4V ELI conforming to ASTM F136 and ISO 5832-3 and Tantalum markers conforming ASTM F560.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

L2-S1

Indicated Patient Age Range

skeletally mature patients

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

The following non-clinical tests were conducted on JULIET®LL: Static axial compression, Static shear compression according to ASTM F2077 and subsidence testing according to ASTM F2267. Results demonstrate that JULIET®LL performs as safely and effectively as its predicate device JULIET®PO.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K081888, K101720, K071795, K081611, K121760, K103666, K090816

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 888.3080 Intervertebral body fusion device.

(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

0

K133557 Page 1 of 2

JULIET® LL

. .

seneart.

FEB - 3 2014

Lateral Lumbar Cage

510(k) SUMMARY

Submitted bySPINEART
International Center Cointrin
20 route de pré-bois
CP1813
1215 GENEVA 15
SWITZERLAND
ContactsFranck PENNESI Director of Industry & Quality
Phone : +41 22 799 40 25 Fax : +41 22 799 40 26
Mail : fpennesi@spineart.com
Regulatory contact : Dr Isabelle DRUBAIX (Idée Consulting)
idrubaix@nordnet.fr
Date PreparedNovember 12th 2013
Common NameIntervertebral body fusion device
Trade NameJULIET® LL Lateral Lumbar Cage
Classification NameIntervertebral Fusion Device With Bone Graft, Lumbar
ClassII
Product CodeMAX
CFR section888.3080
Device panelORTHOPEDIC
Legally marketed
predicate devicesJuliet®PO (K081888 and K101720) manufactured by Spineart
Coroent XL (K071795 and K081611) manufactured by Nuvasive
Capstone (K121760) manufactured by Medtronic
Lanx Fusion System - Lateral (K103666) manufactured by Lanx
AVS PL PEEK AVS Plus -UniLIF (K090816) manufactured by Stryker
Indications for useJULIET®LL Lumbar Interbody Device is indicated for intervertebral body
fusion procedures in skeletally mature patients with degenerative disc
disease (DDD) at one or two contiguous levels from L2-S1. DDD is
defined as discogenic back pain with degeneration of the disc confirmed
by patient history and radiographic studies. These DDD patients may
also have up to Grade 1 spondylolisthesis or retrolisthesis at the
involved level(s). This device is to be used with autogenous bone graft.
JULIET®LL Lumbar Interbody Device is to be used with supplemental
fixation. Patients should have at least six (6) months of non-operative
treatment prior to treatment with an intervertebral cage

1

K133557 Page 2 of 2

:

and the comments of the comments of the comments of the comments of the contraction of the contribution of the contribution of the contribution of the contribution of the con

:

:

Description of the deviceThe JULIET®LL Lateral Lumbar cages are rectangle-shaped intervertebral body fusion devices with a central cavity that can be filled with bone graft (autograft) to facilitate fusion. The JULIET®LL intervertebral body fusion spacer comes in various sizes and footprints in order to fulfill surgeons' needs and accommodate different patient anatomies. The JULIET®LL system is made of PEEK Optima conforming to ASTM F2026 with spikes made of Titanium 6Al-4V ELI conforming to ASTM F136 and ISO 5832-3 and Tantalum markers conforming ASTM F560.
Technological CharacteristicsThe JULIET® LL Lateral Lumbar cages are 21 mm wide and available in five lengths (from 40 to 60 mm) and five heights (from 8 to 16 mm). The JULIET® LL range of lumbar implants are delivered sterile (gamma sterilization) and supplied with dedicated surgical instruments (reusable – provided non sterile).
Discussion of TestingThe following non-clinical tests were conducted on JULIET®LL: Static axial compression, Static shear compression according to ASTM F2077 and subsidence testing according to ASTM F2267. Results demonstrate that JULIET®LL performs as safely and effectively as its predicate device JULIET®PO.
ConclusionThe JULIET® LL is substantially equivalent to its predicate devices in terms of intended use, material, design, mechanical properties and function. The subject and predicate devices have nearly identical technological characteristics and the minor differences do not raise any new issues of safety and effectiveness. Non clinical performance testing demonstrate that JULIET®LL is as safe, as effective, and performs as safely and effectively as its predicate devices.

. . . . . .

.

. :

2

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like symbol with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the symbol.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Jocument Control Center - WO66-G609 Silver Spring, MD 20993-0002

February 3, 2014

Spineart Mr. Franck Pennesi Director of Industry and Quality International Center Cointrin 20 route de pré-bois CP 1813 1215 Geneva 15 SWITZERLAND

Re: K133557

Trade/Device Name: Juliet® LL Lateral Lumbar Cage Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: November 15, 2013 Received: November 19, 2013

Dear Mr. Pennesi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must or any I octar other of the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

3

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Page 2 - Mr. Franck Pennesi

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Vincent Jincent Javlin -S

for

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known) K133557

Device Name

JULIET® LL Lateral Lumbar Cage

Indications for Use (Describe)

JULIET®LL Lumbar Interbody Device is indicated for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). This device is to be used with autogenous bone graft. JULIET®LL Lumbar Interbody Device is to be used with supplemental fixation. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage

Type of Use (Select one or both, as applicable)

[x] Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FOR FOR FOR FOR USE ONLY Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement on last page.

5

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

·············································································································································································· time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."